Old Web
English
Sign In
Acemap
>
authorDetail
>
F Brock
F Brock
UCB
Certolizumab pegol
Internal medicine
Placebo
Medicine
plaque psoriasis
4
Papers
13
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: Results from the randomized phase 3 CIMPACT trial
2021
Journal of The European Academy of Dermatology and Venereology
Richard B. Warren
Mark Lebwohl
Howard Sofen
Vincent Piguet
Matthias Augustin
F Brock
C. Arendt
F Fierens
Andrew Blauvelt
Show All
Source
Cite
Save
Citations (0)
Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomised, Placebo-Controlled Studies.
2020
British Journal of Dermatology
Andrew Blauvelt
Carle Paul
P.C.M. van de Kerkhof
Richard B. Warren
Alice B. Gottlieb
Richard G. Langley
F Brock
C. Arendt
M Boehnlein
Mark Lebwohl
Kristian Reich
Show All
Source
Cite
Save
Citations (6)
Long-Term Efficacy of Certolizumab Pegol for the Treatment of Plaque Psoriasis: Three-Year Results from Two Randomised Phase 3 Trials (CIMPASI-1 and CIMPASI-2).
2020
British Journal of Dermatology
Kenneth B. Gordon
Richard B. Warren
Alice B. Gottlieb
Andrew Blauvelt
Diamant Thaçi
C. Leonardi
Yves Poulin
M Boehnlein
F Brock
C. Ecoffet
Kristian Reich
Show All
Source
Cite
Save
Citations (6)
Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies
2020
Andrew Blauvelt
Carle Paul
P.C.M. van de Kerkhof
Richard B. Warren
Alice B. Gottlieb
Richard G. Langley
F Brock
C. Arendt
M Boehnlein
Mark Lebwohl
Kristian Reich
Show All
Source
Cite
Save
Citations (1)
1